MX348677B - Peptidos ciclicos con actividad antineoplasica y antiangiogenica. - Google Patents

Peptidos ciclicos con actividad antineoplasica y antiangiogenica.

Info

Publication number
MX348677B
MX348677B MX2013010813A MX2013010813A MX348677B MX 348677 B MX348677 B MX 348677B MX 2013010813 A MX2013010813 A MX 2013010813A MX 2013010813 A MX2013010813 A MX 2013010813A MX 348677 B MX348677 B MX 348677B
Authority
MX
Mexico
Prior art keywords
cyclic peptides
systems
neoplasic
angiogenic activity
nanobiotechnology
Prior art date
Application number
MX2013010813A
Other languages
English (en)
Other versions
MX2013010813A (es
Inventor
Acosta Osvaldo Reyes
Santiago Glay Chinea
Diaz Eduardo Martinez
Pérez Maria Del Carmen Abrahantes
Blanco Sonia Gonzalez
Mola Ernesto Lopez
Perez Hilda Elisa Garay
Matilde Lopez Abad Cruz
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2013010813A publication Critical patent/MX2013010813A/es
Publication of MX348677B publication Critical patent/MX348677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a péptidos cíclicos con propiedades antitumorales y antiangiogénicas, así como a sus sales farmacéuticamente aceptables y a las composiciones farmacéuticas que los contienen; estos péptidos cíclicos se emplean en la preparación de medicamentos para la terapéutica humana y/o veterinaria, y también pueden emplearse en el diagnóstico; estos compuestos pueden ser usados para detectar, monitorear y/o controlar una variedad de desórdenes relacionados con la proliferación celular, tales como las enfermedades oncológicas y la angiogénesis no deseada; además, pueden formar parte de sistemas de liberación controlada y en el campo de la nanobiotecnología, ya sea por su capacidad de autoensamblaje o como parte de otros sistemas.
MX2013010813A 2011-03-21 2012-03-21 Peptidos ciclicos con actividad antineoplasica y antiangiogenica. MX348677B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2011000067A CU23950B1 (es) 2011-03-21 2011-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica
PCT/CU2012/000002 WO2012126441A2 (es) 2011-03-21 2012-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica.

Publications (2)

Publication Number Publication Date
MX2013010813A MX2013010813A (es) 2013-10-07
MX348677B true MX348677B (es) 2017-06-23

Family

ID=46000593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010813A MX348677B (es) 2011-03-21 2012-03-21 Peptidos ciclicos con actividad antineoplasica y antiangiogenica.

Country Status (16)

Country Link
US (1) US9375459B2 (es)
EP (1) EP2690107B1 (es)
JP (1) JP6032854B2 (es)
KR (1) KR101958964B1 (es)
CN (1) CN103534265B (es)
AR (1) AR088727A1 (es)
AU (1) AU2012231427B2 (es)
BR (1) BR112013024265B1 (es)
CA (1) CA2830325C (es)
CO (1) CO6801641A2 (es)
CU (1) CU23950B1 (es)
ES (1) ES2644554T3 (es)
MX (1) MX348677B (es)
RU (1) RU2603286C2 (es)
WO (1) WO2012126441A2 (es)
ZA (1) ZA201307037B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001020A (es) * 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
US9340582B2 (en) * 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
CN105612173A (zh) * 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状apelin衍生物
EP3024847A1 (en) * 2013-07-25 2016-06-01 Novartis AG Disulfide cyclic polypeptides for the treatment of heart failure
JP6789823B2 (ja) 2014-04-15 2020-11-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法
CN109503701B (zh) * 2018-07-20 2022-03-15 北京工业大学 一种环肽及其在制备抗肿瘤药物中的应用
CN111662363A (zh) * 2020-06-22 2020-09-15 上海大学 环肽类抗肿瘤活性化合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536604A1 (en) 2002-08-30 2004-03-11 Biopharmacopae Design International Inc. Plant extracts for treatment of angiogenesis and metastasis
CU23475A1 (es) 2004-07-08 2009-12-17 Ct Ingenieria Genetica Biotech Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
WO2007022557A1 (en) * 2005-08-23 2007-03-01 Diatech Pty Ltd Mimotopes of epstein-barr virus (ebv) epitopes
EP1951279B1 (en) * 2005-10-08 2017-04-12 Apellis Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
ITTO20060852A1 (it) * 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
CN102264755A (zh) * 2007-08-08 2011-11-30 得克萨斯大学体系董事会 靶向vegfr-1/nrp-1的肽
BRPI0915718A2 (pt) * 2008-06-20 2017-06-20 Univ Texas peptídeos de direção crkl
US20100015058A1 (en) * 2008-06-25 2010-01-21 Stanford University Radiolabeled bbn-rgd heterodimers for cancer targeting

Also Published As

Publication number Publication date
CN103534265A (zh) 2014-01-22
EP2690107B1 (en) 2017-08-02
CU23950B1 (es) 2013-10-29
ES2644554T3 (es) 2017-11-29
RU2013146690A (ru) 2015-04-27
MX2013010813A (es) 2013-10-07
KR20140042796A (ko) 2014-04-07
US9375459B2 (en) 2016-06-28
WO2012126441A3 (es) 2012-11-22
ZA201307037B (en) 2014-06-25
CA2830325C (en) 2019-09-10
CO6801641A2 (es) 2013-11-29
AR088727A1 (es) 2014-07-02
BR112013024265A2 (pt) 2016-12-27
CA2830325A1 (en) 2012-09-27
CU20110067A7 (es) 2012-10-15
JP6032854B2 (ja) 2016-11-30
JP2014513066A (ja) 2014-05-29
WO2012126441A2 (es) 2012-09-27
KR101958964B1 (ko) 2019-07-02
AU2012231427B2 (en) 2016-08-04
AU2012231427A1 (en) 2013-10-03
US20140112976A1 (en) 2014-04-24
EP2690107A2 (en) 2014-01-29
CN103534265B (zh) 2016-06-08
BR112013024265B1 (pt) 2020-12-08
RU2603286C2 (ru) 2016-11-27

Similar Documents

Publication Publication Date Title
MX348677B (es) Peptidos ciclicos con actividad antineoplasica y antiangiogenica.
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
EP4324479A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
EP2849770A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE DISPOSAL OF ESSENTIALLY WATER-INSOLICED MEDICINAL PRODUCTS
PH12015501096A1 (en) Composition for immediate and extended release
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
UA117154C2 (uk) Антагоністи s1p3
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
MX353623B (es) Sistema de suministro de farmaco.
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2015007731A (es) Formulacion farmaceutica que comprende ciclesonida.
EP2682129A3 (en) Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.

Legal Events

Date Code Title Description
FG Grant or registration